Albireo Pharma (ALBO) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free ALBO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 6, 2024 | businesswire.comAlbireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and ReliabilityJanuary 19, 2024 | bizjournals.comProspect Park II in Fort LauderdaleOctober 1, 2023 | investing.comALBO Historical DataMarch 30, 2023 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) Coverage Initiated by Analysts at StockNews.comStockNews.com started coverage on shares of Albireo Pharma in a research report on Thursday. They issued a "sell" rating for the company.March 27, 2023 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Receives Consensus Rating of "Hold" from AnalystsAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) has been given an average rating of "Hold" by the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy ratMarch 14, 2023 | marketbeat.comStockNews.com Begins Coverage on Albireo Pharma (NASDAQ:ALBO)StockNews.com started coverage on shares of Albireo Pharma in a research note on Tuesday. They set a "sell" rating on the stock.March 4, 2023 | finanznachrichten.deIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioMarch 3, 2023 | marketbeat.comFederated Hermes Inc. Has $43.72 Million Position in Albireo Pharma, Inc. (NASDAQ:ALBO)Federated Hermes Inc. increased its position in Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 0.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,258,124 shares of the biopharmaceutical company's stock after buying an additional 3,000 sharMarch 3, 2023 | marketbeat.comShort Interest in Albireo Pharma, Inc. (NASDAQ:ALBO) Declines By 19.8%Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 553,900 shares, a drop of 19.8% from the January 31st total of 690,300 shares. Based on an average daily trading volume, of 445,800 shares, the short-interest ratio is currently 1.2 days.March 1, 2023 | marketbeat.comTower Research Capital LLC TRC Boosts Stock Holdings in Albireo Pharma, Inc. (NASDAQ:ALBO)Tower Research Capital LLC TRC boosted its position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 560.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,732 shares of theFebruary 27, 2023 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Stock Position Trimmed by ExodusPoint Capital Management LPExodusPoint Capital Management LP decreased its position in Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 32.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 35,874 shares of the biopharmaceutical company's stFebruary 25, 2023 | seekingalpha.comALBO Albireo Pharma, Inc.February 24, 2023 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires New Shares in Albireo Pharma, Inc. (NASDAQ:ALBO)Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,061 shares of the biopharmaceutical company'sFebruary 18, 2023 | uk.finance.yahoo.comAlbireo Pharma, Inc. (ALBO)February 16, 2023 | marketbeat.comPrudential Financial Inc. Sells 41,800 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO)Prudential Financial Inc. lowered its position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 61.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,700 shares of the biopharmaceutical company's stock after selling 41,February 14, 2023 | marketwatch.comAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOFebruary 14, 2023 | finance.yahoo.comFDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeJanuary 27, 2023 | marketbeat.comDekaBank Deutsche Girozentrale Grows Position in Albireo Pharma, Inc. (NASDAQ:ALBO)DekaBank Deutsche Girozentrale increased its position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 28.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,000 shares of the biopharmaceutical comJanuary 24, 2023 | reuters.comALBO.PH - | Stock Price & Latest News | ReutersJanuary 21, 2023 | finance.yahoo.comWhy These Two Biotech Stocks Blasted Higher This WeekJanuary 13, 2023 | marketbeat.comHC Wainwright Weighs in on Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - HC Wainwright issued their FY2027 earnings estimates for Albireo Pharma in a research report issued to clients and investors on Tuesday, January 10th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will earn $19.05 per shJanuary 11, 2023 | msn.comCowen & Co. Downgrades Albireo Pharma: Here's What You Need To KnowJanuary 11, 2023 | msn.comAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisitionJanuary 11, 2023 | nasdaq.comAlbireo Pharma Spikes On Agreement To Be Acquired By IpsenJanuary 11, 2023 | markets.businessinsider.comExpert Ratings for Albireo PharmaJanuary 11, 2023 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) Rating Lowered to Neutral at GuggenheimGuggenheim downgraded Albireo Pharma from a "buy" rating to a "neutral" rating in a report on Wednesday.January 10, 2023 | marketbeat.comEquities Analysts Issue Forecasts for Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - Stock analysts at Wedbush issued their FY2027 earnings per share estimates for shares of Albireo Pharma in a note issued to investors on Monday, January 9th. Wedbush analyst A. Argyrides expects that the biopharmaceutical company will post earningJanuary 9, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with IpsenJanuary 9, 2023 | technews.tmcnet.comALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to ShareholdersJanuary 9, 2023 | finance.yahoo.comFrance-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, PipelineJanuary 2, 2023 | seekingalpha.comAlbireo: Slowly Capturing Some Of The Liver Disease MarketDecember 21, 2022 | finance.yahoo.comWe're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn RateDecember 6, 2022 | finance.yahoo.comAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNovember 30, 2022 | finance.yahoo.comReimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2November 14, 2022 | marketbeat.comFY2022 Earnings Estimate for Albireo Pharma, Inc. (NASDAQ:ALBO) Issued By William BlairAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - Stock analysts at William Blair upped their FY2022 earnings estimates for shares of Albireo Pharma in a note issued to investors on Wednesday, November 9th. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will postNovember 10, 2022 | finance.yahoo.comAlbireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investorsNovember 9, 2022 | finance.yahoo.comAlbireo to Participate in Jefferies London Healthcare ConferenceNovember 9, 2022 | seekingalpha.comAlbireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comAlbireo Reports Q3 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comAlbireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue EstimatesNovember 7, 2022 | finance.yahoo.comBylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNovember 3, 2022 | finance.yahoo.comAlbireo Announces 2022 SPARK Grant WinnersNovember 2, 2022 | finance.yahoo.comAlbireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNovember 1, 2022 | finance.yahoo.comAlbireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022October 31, 2022 | finance.yahoo.comAlbireo to Report Q3 2022 Financial Results on November 8, 2022October 25, 2022 | finance.yahoo.comAnalysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's PenetrationOctober 25, 2022 | marketbeat.comInsider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) CEO Sells 919 Shares of StockAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) CEO Ronald Harold Wilfred Cooper sold 919 shares of the company's stock in a transaction on Monday, October 24th. The shares were sold at an average price of $19.58, for a total value of $17,994.02. Following the completion of the transaction, the chief executive officer now owns 55,461 shares of the company's stock, valued at $1,085,926.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.October 17, 2022 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) Price Target Raised to $59.00 at GuggenheimOctober 15, 2022 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Down 13.3% in SeptemberOctober 14, 2022 | marketbeat.comQ3 2022 EPS Estimates for Albireo Pharma, Inc. (NASDAQ:ALBO) Increased by AnalystAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - Research analysts at Jefferies Financial Group raised their Q3 2022 EPS estimates for Albireo Pharma in a research note issued on Tuesday, October 11th. Jefferies Financial Group analyst E. Yang now anticipates that the biopharmaceutical company w Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address The only financial event in 2024 that matters (Ad)Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral. Stream the documentary for free by clicking here ALBO Media Mentions By Week ALBO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALBO News Sentiment▼0.200.76▲Average Medical News Sentiment ALBO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALBO Articles This Week▼00▲ALBO Articles Average Week Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: COLL News ANAB News VNDA News GOSS News VBIV News AXSM News MRUS News RARE News INSM News HCM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALBO) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
